- First edition of PSYCH Investor Summit: Europe & Asia to connect psychedelics
healthcare businesses with leading European and APAC investors and funds.
- Keynote presentation by Professor David Nutt, Director of
Neuropsychopharmacology at Imperial College London, and other renowned industry
experts will share key insights to promote the potential of psychedelics in
16th April 2021, London - PSYCH, the premier market intelligence and events firm that
aims to unlock the potential of psychedelics in healthcare, is launching the PSYCH Investor
Summit: Europe & Asia. The virtual event, powered by industry-leaders in cannabis and
psychedelics data intelligence Prohibition Partners, aims to promote the potential of
psychedelics in the healthcare industry and provide businesses the opportunity to showcase
their projects directly to European and APAC investors and funds.
In light of the ongoing COVID-19 pandemic, the importance of mental health is increasingly
in the spotlight, and as consumers look for new options to improve their mental health, the
growing significance of the potential of psychedelics is pushing the healthcare industry to
respond with solutions. The global psychedelics industry is expected to be worth over
US$100 billion, and as attitudes towards psychedelics shift dramatically, we are witnessing
an international rise in clinical trials, academic research and commercial investment.
The PSYCH Investor Summit: Europe & Asia, taking place on the 21st April, will examine
how new therapies are tackling the mental health pandemic, why microdosing is set to
disrupt the mainstream and how legislation is expected to develop in seminal markets.
Participants will also have the opportunity to engage with distinguished industry leaders,
rising entrepreneurs and global psychedelics investors to share insights and help push
forward this increasingly relevant industry.
According to PSYCH co-founder Stephen Murphy, “The heightened focus on finding better
solutions for mental health conditions that psychedelics can treat, combined with a wave of
ongoing research that is coming to fruition, is leading to rapid rates of acceptance in
mainstream medicine and increased investor interest. As an industry backed by science with
the potential to revolutionise healthcare, PSYCH's purpose is to contribute to the
advancement of this emerging frontier, while supporting the growth of businesses and giving
them the opportunity to achieve global recognition for their groundbreaking
Following on from the success of previous Prohibition Partners virtual events in 2020, which
saw over 2,500 delegates attend to hear from over 270 speakers, the PSYCH keynote
speech will be given by renowned Professor David Nutt, Director of
Neuropsychopharmacology, Imperial College London, and Head of Research, Awakn Life
Sciences, who will guide the audience through the exciting developments within the industry
and the pioneering research being carried out across Psychedelic Medicine in Europe.
Other industry experts speaking at the event include Ronan Levy, Co-Founder & Executive
Chairman, Field Trip Health Ltd.; Anthony Tennyson, CEO of Awakn Life Sciences; Richard
Cheung, General Counsel at Noetic Fund; Tim Schlidt, Partner at Palo Santo; Victoria
Dekker, Head of Growth at PSYCH; Peter Reitano, CEO of Gwella: Nick Murray, Co-Founder
& CEO of Wake Network; Yeji Jesse Lee, Journalist for Business Insider; Greg Kubin,
Founder & Host of Business Trip; and Conor O’Brien, Industry & Data Analyst for Prohibition
With the aim of facilitating investment channels, the promoted companies will present to an
audience of investors in 10-minute pitch slots followed by a 10-minute Q&A session, and will
have the opportunity to be directly introduced to companies and individuals actively looking
- Awakn Life Sciences - Specialises in the integration of psychedelic medicine into
mainstream healthcare to enable better mental health for more people through
research, clinics and ecosystems.
- Field Trip - Aims to bring the world to life through psychedelics and
- Gwella - Making mushrooms for modern life, its mission is to build the most
accessible and original over-the-counter portfolio of functional and psychedelic
mushroom products that amplify individual and community wellness.
- Wake Network - Wake is advancing the field of fungi biosciences and is
developing a personalized, genetics-based approach to therapeutics and
Partners will also be included in the PSYCH: The Psychedelics as Medicine Report,
currently in its second edition. The report profiles most major psychedelic substances —
both naturally derived entheogens and synthetically manufactured psychedelics — and
outlines the current state of worldwide regulatory frameworks, clinical trials, and commercial
opportunities associated with these compounds.
The leading global source for psychedelics market intelligence, PSYCH empowers
operators, regulators and investors to make informed decisions. Our work intersects
knowledge and networks, providing access to trustworthy data, independent sector analysis
and engaging events. Powered by Prohibition Partners, the definitive source of data
intelligence and strategy for the global cannabis and psychedelics industries, PSYCH exists
to stimulate meaningful change in modern healthcare through trusted market intelligence.
For more information, please visit the PSYCH Investor Summit: Europe & Asia website.
For Media Enquiries:
Head of Communications
+34 633 663 699
For Event and Sponsorship Enquiries:
Event and Sponsorship Lead
+34 645 116 528
For PSYCH Enquiries:
Head of Growth
+1 (506) 962-6565
© 2021 PP Intelligence LTD. A Prohibition Holdings Company. 31 New Inn Yard, Shoreditch London EC2A 3EY psych.prohibitionpartners.com | email@example.com
Press release distributed by Pressat on behalf of Prohibition Partners, on Friday 16 April, 2021. For more information subscribe and follow https://pressat.co.uk/